Immediate Impact

2 from Science/Nature 57 standout
Sub-graph 1 of 24

Citing Papers

Pyroptosis‐Mediated Synergistic Photodynamic and Photothermal Immunotherapy Enabled by a Tumor‐Membrane‐Targeted Photosensitive Dimer
2023 Standout
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
2020 Standout
3 intermediate papers

Works of John C. Brady being referenced

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.
2016
Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).
2013
and 2 more

Author Peers

Author Last Decade Papers Cites
John C. Brady 117 89 131 119 18 479
María Carolina Cabrera Schulmeyer 160 33 101 51 21 425
Neil Lambie 96 65 118 162 23 459
U. Junker 101 93 161 208 19 504
C Natter 89 54 52 220 14 412
Jenny Rubin 63 38 89 88 14 469
Misato Amenomori 191 97 259 85 18 574
L J Farrow 118 32 97 139 15 457
Jao W 142 77 92 136 21 560
Hui Ye 109 135 86 85 23 468
Francisco J. Leyva 79 138 96 142 18 414

All Works

Loading papers...

Rankless by CCL
2026